# CS1008- in Combination With Sorafenib Compared to Sorafenib Alone in Subjects With Advanced Liver Cancer

> **NCT01033240** · PHASE2 · COMPLETED · sponsor: **Daiichi Sankyo** · enrollment: 172 (actual)

## Conditions studied

- Advanced Hepatocellular Carcinoma
- Liver Cancer
- Hepatic Cancer
- Liver Neoplasms

## Interventions

- **DRUG:** CS-1008 2 mg/kg
- **DRUG:** Sorafenib
- **DRUG:** CS-1008 6/2 mg/kg
- **DRUG:** CS-1008 6/6 mg/kg
- **DRUG:** CS-1008 4 mg/kg
- **DRUG:** CS-1008 6 mg/kg

## Key facts

- **NCT ID:** NCT01033240
- **Lead sponsor:** Daiichi Sankyo
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-07-09
- **Primary completion:** 2012-07-13
- **Final completion:** 2013-09-09
- **Target enrollment:** 172 (ACTUAL)
- **Last updated:** 2021-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01033240

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01033240, "CS1008- in Combination With Sorafenib Compared to Sorafenib Alone in Subjects With Advanced Liver Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01033240. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*